Abstract
The aim of the present work is to develop extended-release capsules of Galantamine HBr (8mg) and compare them with the reference listed drug (Reminyl or Razadyne). The capsules were prepared using Pelletization technique and evaluated for preformulation characteristics, physical, and chemical parameters. The In-vitro dissolution studies were conducted using USP type II (paddle apparatus) in 900 ml of pH 6.5 phosphate buffer. Among all the formulations, F7 was found to be pharmaceutically equivalent to reference listed drug due to its similarity factor (f2= 96) in drug release profile. The F7 formulation was loaded for stability study and no change was observed, which indicates that the optimized F7 formulation was stable.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
